A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment.

Trial Profile

A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms STAGE
  • Sponsors Genentech
  • Most Recent Events

    • 16 Jul 2016 This trial has been completed in Belgium, Germany, Spain, Austria with end date as 2015-04-22 and Greece as per European Clinical Trials Database record.
    • 22 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 06 Jan 2014 Planned End Date changed from 1 Jun 2010 to 1 Dec 2014 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top